CompletedNot Applicable

Recombinant Activated Factor VII in the Management of Massive Bleeding in Hospital Universiti Sains Malaysia

Malaysia76 participantsStarted 2017-08-21

Plain-language summary

This is a retrospective descriptive study, to study the treatment indications, changes in transfusion need, coagulation profiles changes and clinical outcome (survival, complication) of non-haemophiliac patients who received activated factor seven (rFVIIa / NovoSeven®) during massive bleeding in Hospital Universiti Sains Malaysia (HUSM)

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All patient with massive bleeding who had received rFVIIa from year 2006 to year 2016. * Massive bleeding criteria * Loss of one blood volume within a 24 hour * 50% blood volume loss within 3 h * Rate of loss of 150 ml/min Exclusion Criteria: * Haemophilia patient who received rFVIIa * Poor documentation / record unavailable in HUSM

What they're measuring

Changes in blood transfusion requirement

Timeframe: 24 hour before and after administration of rFVIIa

Survival rate

Timeframe: 30 days

Trial details

NCT IDNCT03251547

SponsorUniversiti Sains Malaysia

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2017-10-15

View on ClinicalTrials.gov More Massive Hemorrhage trials